{
    "2020-04-22": [
        [
            {
                "time": "2018-03-15",
                "original_text": "AbbVie (ABBV) Gains But Lags Market: What You Should Know",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Gains",
                        "Lags Market"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-04-10",
                "original_text": "Were Hedge Funds Right About AbbVie Inc (ABBV)?",
                "features": {
                    "keywords": [
                        "Hedge Funds",
                        "Right",
                        "AbbVie"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-20",
                "original_text": "Healthcare ETFs Looks Strong Ahead of Q1 Earnings",
                "features": {
                    "keywords": [
                        "Healthcare",
                        "ETFs",
                        "Strong",
                        "Q1 Earnings"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-05",
                "original_text": "Form 8.3 - Abbvie Inc - Amendment",
                "features": {
                    "keywords": [
                        "Form 8.3",
                        "Amendment",
                        "Abbvie Inc"
                    ],
                    "sentiment_score": 0.0,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-05-10",
                "original_text": "Form 8.3 - ABBVIE INC",
                "features": {
                    "keywords": [
                        "Form 8.3",
                        "ABBVIE INC"
                    ],
                    "sentiment_score": 0.0,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-06-01",
                "original_text": "AbbVie Gets FDA Nod for Imbruvica+Rituxan in First-Line CLL",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "FDA Nod",
                        "Imbruvica+Rituxan",
                        "First-Line CLL"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-06-15",
                "original_text": "Form 8.3 - AbbVie Inc.",
                "features": {
                    "keywords": [
                        "Form 8.3",
                        "AbbVie Inc."
                    ],
                    "sentiment_score": 0.0,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}